Last reviewed · How we verify
NCT04497701
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
NA trial testing PEG-rhG-CSF group in Lymphoma in 139 participants. Status unknown.
1 August 2021
Quick facts
| Lead sponsor | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 139 |
| Start date | 1 August 2020 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- PEG-rhG-CSF group
- rhG-CSF group
Conditions studied
Sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. — full company profile →
Who can join
Under 18, any sex, with Lymphoma or Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of infectious complications in hematological malignancies is higher than that in children with solid tumors, which may be related to the type and dose intensity of chemotherapy regimens used in hematological tumors. The treatment of childhood cancer has changed in the past few decades: intensive treatment and good supportive treatment can improve the 5-year survival rate of children. The aim of this study was to evaluate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) after chemotherapy in children with hematological malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04497701
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07420257 — A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participa · Phase 3 · not yet recruiting
- NCT07372287 — A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma · Phase 3 · not yet recruiting
- NCT06830343 — The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity · Phase 1 · recruiting
- NCT06604624 — Semaglutide in Treatment of Obesity · Phase 3 · completed
- NCT06258148 — A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04497701 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Last refreshed: 4 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04497701.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing